Eyebright Medical(SH:688050) Xin Lang Ji Jin·2025-06-26 03:59Group 1 - The article highlights that three public funds, namely ICBC Credit Suisse Fund, Yongying Fund, and E Fund, have reported paper losses from their locked shares in recent private placements, totaling approximately 6.6 million yuan [1][2] - Specifically, ICBC Credit Suisse Fund has a loss of about 296.07 thousand yuan, Yongying Fund has a loss of approximately 249.02 thousand yuan, and E Fund has a loss of around 114.76 thousand yuan [1][2] - The funds participated in one or more private placement projects, with the number of locked stocks being 1 for ICBC Credit Suisse and Yongying Funds, and 3 for E Fund [1][2] Group 2 - The data indicates that ICBC Credit Suisse Fund invested 24.477 million yuan in a private placement for Aibo Medical (688050.SH), with the lock-up period starting on May 12, 2025, and ending on November 13, 2025 [3] - Yongying Fund also participated in the same private placement for Aibo Medical, investing 20.587 million yuan, with identical lock-up dates [4] - E Fund engaged in two private placements, including Aibo Medical and Zhongtung High-tech (000657.SZ), investing 9.4871 million yuan in Aibo Medical, with the same lock-up period [5] Group 3 - The article notes that the primary source of the current public fund losses is linked to the private placement investments, which inherently carry risks due to the lock-up periods and market volatility [6] - It is mentioned that the attractiveness of private placements for companies is diminishing, as they may incur higher costs compared to other financing methods, such as debt financing, which does not dilute existing shareholders' equity [7] - Current market conditions, including low interest rates for bank loans and bond issuances, further reduce the incentive for companies to opt for private placements [7]